Sponsors – 6th Clinical Trials Phase I & Phase IIA Summit

Do you want to spread the word about your organization’s solutions and services to potential clients who will be attending this event? Take advantage of the opportunity to exhibit, underwrite an educational session, host a networking event or distribute promotional items to attendees. ExL Events will work closely with you to customize a package that will suit all of your needs.

To learn more about these opportunities, please contact Andrew Sinetar at 212-400-6237 or [email protected].

CATALIS – Quebec Clinical Trials

CATALIS is a non-profit partnership dedicated to the advancement and operational excellence of early-stage clinical research in Quebec, Canada. Our mission is to promote Quebec’s unique expertise and cutting-edge infrastructure in order to accelerate the development of innovative drugs for patients.

Early-Stage Clinical Trials in Quebec. The Smart Choice for You.

Website: https://www.catalisquebec.com/en/


Covance Inc., the drug development business of Laboratory Corporation of America Holdings (LabCorp) headquartered in Princeton, New Jersey, USA, is the world’s most comprehensive drug development company, dedicated to advancing healthcare and delivering Solutions Made Real®. Information on Covance’s solutions can be obtained through its website at www.covance.com.

Website: http://www.covance.com/

Phase Clinical Services

Phase Clinical Services is an innovative full service CRO focusing on Phase 0-II oncology clinical trials. Exclusive overseas access to 50k+ oncology patients per year, close collaboration with top government officials and effective local teams ensure timely trial completion. Exceptionally competitive rates and clinical trial management from New York City.

Website: https://www.phaseclinical.com/


SOUSEIKAI is a hospital-based clinical trial center in Japan, which is currently ranked as the 6th largest site in the world (420 dedicated beds for clinical trials). For the last decade only, about 600 early phase studies including 53 FIH studies, were conducted at our site. Our rigorous compliance with ICH-GCP and Japanese GCP has been proven in the past 58 GCP inspections from USFDA, KFDA, and PMDA with the results of all NAI.

Website: http://www.lta-med.com/SouseikaiGlobal/